Unique opportunities for Pharma/Biotech companies to develop their orphan drugs in Japan

•       New Major Policy Changes introduced by MHLW to promote the development of Orphan Drugs in Japan

•       It may be possible to skip Phase 1 in Japanese in order to include Japan in phase 3 global clinical trial

•       Tap into Yakumed’s expertise in Orphan Drugs to plan, strategize and execute Japan market entry, development and regulatory approval